Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease

NCT07061938 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

IgG4 Related Disease

Interventions

DRUG: ACE1831
DRUG: Lymphodepleting chemotherapy

Sponsor

Acepodia Biotech, Inc.